Real demand
It replaces the pain of injections, blood draws and IVF shots, and the reliance on painkillers; hospitals and patients keep buying, with 31 million needle procedures reportedly blocked. Revenue comes from real payers, not a concept.
Real-revenue cases
How A Doctor Got On Shark Tank And Saved 31M People From Pain -
Real demandA pediatric ER doctor built Buzzy, a vibrating ice-pack device that blocks needle pain, sold to hospitals and home-care users, and reached roughly $208K in monthly revenue while funding R&D and early growth through NIH grants and pitch-contest prizes.
- Primary source
- View original
01
Real-demand verdict
Hospitals and home users buy Buzzy and later VibraCool devices through the company's own store and channels; R&D and early runway came mainly from NIH SBIR grants and pitch-contest prizes ($15K from Huggies, $250K from Chase).
Pain from injections, blood draws and IVF shots, plus post-surgery reliance on painkillers including opioids.
02
Where the first customers came from
After the 2009 launch, word spread through hospital research backing and internal champions, selling first to hospitals and early parent users.
03
Tactics you can copy
- 01Fund R&D with non-dilutive grants like NIH SBIR, buying time before raising or scaling.
- 02Recruit clinical champions inside hospitals so professional endorsement replaces ad spend.
- 03Use pitch-contest prizes (Huggies, Chase) to cover early marketing and design debts during cold start.
Moving it to an AI business
The non-dilutive-grant plus expert-endorsement cold start transfers to health and medical AI apps: cover model and compliance costs with research or industry funding first, then acquire users through clinician or expert word of mouth instead of paid ads.
04
Evidence and limits
Founder interview, self-reported
Revenue basis · Founder self-reported, unaudited (see source page)
What evidence is missing
The $208K monthly revenue is founder self-reported and unaudited; the source gives no gross margin or repeat-purchase rate.
The material does not break down revenue between hospital procurement and direct-to-family sales.
The '31 million needle procedures' figure is cumulative usage, not paying users or units sold.
Primary source